|
CN107474097A
|
|
With antitumor action enoxolone cinnamic acid derivative（GA‑CA）Preparation method and applications
|
|
CN106977464A
|
|
Ligustrazine substituted cinnamic acid analog derivative (LQC-W) and its application with neuroprotective activity
|
|
CN105596337A
|
|
New uses of tetramethylpyrazine derivative in biological nerve protection
|
|
CN105315321A
|
|
Compound having antitumor effect, preparation method and application thereof
|
|
CN104557740A
|
|
Ligustrazine substituted benzoic acid derivative (LQC-A) with neuroprotective activity and application of ligustrazine substituted benzoic acid derivative
|
|
WO2013063755A1
|
|
Oligopeptide for treating liver fibrosis and/or hepatitis b and/or improving liver function
|
|
CN102675228A
|
|
Medicine for treating ischemic brain injury stroke and sequela of ischemic brain injury stroke and preparation method for medicine
|
|
CN102675401A
|
|
Preparation of anti-tumor medicine LQC-Y and application thereof
|
|
CN104151388A
|
|
Preparation of anti-tumor drug LQC-Y and application thereof
|
|
CN102675403A
|
|
Synthesis of anti-hepatitis B medicine LQC-X and application thereof
|
|
CN102268066B
|
|
Anti-HBV oligopeptides and derivatives thereof
|
